Sean Robert Bennett, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

How participatory is parental consent in low literacy rural settings in low income countries? Lessons learned from a community based study of infants in South India.
BMC Med Ethics.
Volume: 12:3
Date: 02 2011

Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine
Vaccine
2013 Aug 20;31(37):4024-32.
Date: 08 2013
www.journals.elsevier.com/vaccine/

Two-step tuberculin skin testing in school-going adolescents with initial 0-4 millimeter responses in a high tuberculosis prevalence setting in South India.
PLoS One
2013 Sep 6;8(9)
Date: 09 2013
www.plosone.org

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
Vaccine
2013 Nov 4;31(46):5300-5.
Date: 11 2013
www.journals.elsevier.com/vaccine/

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Vaccine
2013 Nov 4;31(46):5306-13
Date: 11 2013
www.journals.elsevier.com/vaccine/

b. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Vaccine
2015 Jul 9;33(30):3592-9.
Date: 07 2015

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Vaccine
Volume: 35
Date: 03 2017

Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial
Vaccine
Volume: 37
Date: 03 2019
10.1016/j.vaccine.2019.01.077

Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years
AJTMH
Volume: 102
Date: 01 2020
10.4269/ajtmh.19-0241

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial
Lancet Infectious Diseases
Volume: 22
Date: 06 2022
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00226-2/fulltext